Coulter Partners secures Chief Executive Officer for Biogazelle
Coulter Partners was very pleased to partner with Biogazelle, specialists in liquid biopsies and non-coding RNA, to secure the appointment of Armin Winands as its new Chief Executive Officer. He follows co-founder Jan Hellemans, who will take on the role of CTO after 10 years as CEO.
The appointment of Armin Winands is part of Biogazelle’s strategy to position itself as a respected European player in the field of molecular test discovery, development and analysis. With its internationally recognized expertise in gene expression and liquid biopsies, Biogazelle’s unique service offering is a valuable contribution to the field of precision medicine.
Armin Winands is a highly experienced, successful and well-regarded business leader. He has gained experience in the markets of genetic testing, biomarker discovery and clinical assay development since 2010 and has built expertise in building and leading international teams for over 20 years. Winands is a people- and customer-focused individual with a strong history of managing highly engaged and results oriented teams. He looks forward to leading the company through its next phase of innovation and spur rapid growth.
“I am incredibly proud and excited to lead Biogazelle and execute our global strategy following our vision of becoming a highly valued partner to our customers developing diagnostics and therapeutics. Biogazelle has a fantastic business and with its expertise in biomarker discovery, clinical assay development and liquid biopsies we are set up very well to serve our customers. The deep pool of talent, motivation and customer focus differentiates our team and makes us the preferred partner for our customers,” comments Armin Winands, PhD, newly appointed CEO of Biogazelle.
Since first offering qPCR services to its clients in 2011, Biogazelle’s ambition has been to deliver outstanding quality and technically valid results. More recently, Biogazelle has broadened its activities towards molecular test development, further building on years of experience in quantitative PCR and RNA sequencing of clinical samples. With its innovative service, Biogazelle targets pharmaceutical companies, central labs and contract research organizations aiming at incorporating biomarker analyses in various therapeutic areas.
“The last few years, we have been working hard to establish a state-of-the art technology offer in a professional organization with all applicable quality assurance measures in place. Going forward, I am eager to welcome Armin as CEO and I thank the highly professional team at Coulter Partners for their work on our behalf in achieving this appointment. Armin’s demonstrated talents to lead commercial teams will be essential for the continued growth of Biogazelle in an international context,” adds Jan Hellemans, PhD, CTO and co-founder of Biogazelle.
Biogazelle, specialized in liquid biopsies and (non-coding) RNA, supports scientists in the development of diagnostics and therapeutics by offering innovative solutions in a quality environment. Biogazelle offers expert genomic and transcriptomic services performed in an ISO17025 accredited and GCLP-compliant laboratory to support research, clinical trials and precision medicine.
For further information please visit: https://www.biogazelle.com/